Anthera Pharmaceuticals, Inc. (ANTH)

0.05
OTC Markets
Prev Close 0.05
Day Low/High 0.04 / 0.05
52 Wk Low/High 0.01 / 0.10
Exchange OTC Markets
Shares Outstanding 26.18B
Market Cap 1.27M
Div & Yield N.A. (N.A)

Latest News

Jim Cramer: Valuations Now Have No Relation to Common Sense

Jim Cramer: Valuations Now Have No Relation to Common Sense
Anthera Pharmaceuticals Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura

Anthera Pharmaceuticals Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura
Anthera Pharmaceuticals To Present At The 30TH Annual ROTH Conference

Anthera Pharmaceuticals To Present At The 30TH Annual ROTH Conference

Anthera Pharmaceuticals Deemed Compliant With Nasdaq Listing Criteria

Anthera Pharmaceuticals Deemed Compliant With Nasdaq Listing Criteria

Anthera Pharmaceuticals Provides Business Update And Reports 2017 Fourth Quarter And Fiscal Year Financial Results

Anthera Pharmaceuticals Provides Business Update And Reports 2017 Fourth Quarter And Fiscal Year Financial Results

Anthera Pharmaceuticals To Participate In The BIO CEO & Investor Conference And SunTrust Robinson Humphrey's 4th Annual Orphan Drug Day

Anthera Pharmaceuticals To Participate In The BIO CEO & Investor Conference And SunTrust Robinson Humphrey's 4th Annual Orphan Drug Day

Anthera Concludes Last Patient Visit In The Phase 3 RESULT Clinical Study Of Sollpura

Anthera Concludes Last Patient Visit In The Phase 3 RESULT Clinical Study Of Sollpura

Anthera Receives Positive Nasdaq Listing Determination

Anthera Receives Positive Nasdaq Listing Determination

Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 RESULT Clinical Study Of Sollpura: Study On Schedule For Topline Data This Quarter

Anthera Announces Positive Outcome Of Second Interim Futility Analysis In The Phase 3 RESULT Clinical Study Of Sollpura: Study On Schedule For Topline Data This Quarter

Anthera Pharmaceuticals Announces Second Closing Of $15 Million Private Placement Offering

Anthera Pharmaceuticals Announces Second Closing Of $15 Million Private Placement Offering

Anthera Pharmaceuticals Announces Results Of Special Meeting Of Stockholders

Anthera Pharmaceuticals Announces Results Of Special Meeting Of Stockholders

Anthera Pharmaceuticals Announces Appointment Of Patrick Murphy As Senior Vice President, Manufacturing

Anthera Pharmaceuticals Announces Appointment Of Patrick Murphy As Senior Vice President, Manufacturing

Anthera Pharmaceuticals Announces Positive Outcome Of Interim Futility Analysis In The Phase 3 RESULT Clinical Study Of Sollpura

Anthera Pharmaceuticals Announces Positive Outcome Of Interim Futility Analysis In The Phase 3 RESULT Clinical Study Of Sollpura

Anthera Pharmaceuticals Announces Receipt Of Nasdaq Listing Determination Notice And Plans Appeal

Anthera Pharmaceuticals Announces Receipt Of Nasdaq Listing Determination Notice And Plans Appeal

Anthera Pharmaceuticals Announces Completion Of Recruitment In The Phase 3 RESULT Clinical Study Of Sollpura

Anthera Pharmaceuticals Announces Completion Of Recruitment In The Phase 3 RESULT Clinical Study Of Sollpura

Anthera Pharmaceuticals Provides Business Update And Reports 2017 Third Quarter Financial Results

Anthera Pharmaceuticals Provides Business Update And Reports 2017 Third Quarter Financial Results

Anthera Pharmaceuticals Announces Presentation Of Blisibimod Data At The American College Of Rheumatology Annual Meeting

Anthera Pharmaceuticals Announces Presentation Of Blisibimod Data At The American College Of Rheumatology Annual Meeting

Presentation will highlight additional analyses of the CHABLIS-SC1, Phase 3 clinical study of blisibimod

Anthera Pharmaceuticals Announces Presentations Of Sollpura Data At The North American Cystic Fibrosis Conference

Anthera Pharmaceuticals Announces Presentations Of Sollpura Data At The North American Cystic Fibrosis Conference

Anthera Pharmaceuticals Announces Presentation Of Blisibimod Lupus Research At The American Society Of Nephrology Annual Meeting

Anthera Pharmaceuticals Announces Presentation Of Blisibimod Lupus Research At The American Society Of Nephrology Annual Meeting

Presentation to highlight data from the CHABLIS-SC1, Phase 3 clinical study of blisibimod

Anthera Pharmaceuticals Announces Pricing Of $15 Million Private Placement Offering

Anthera Pharmaceuticals Announces Pricing Of $15 Million Private Placement Offering

Russell 2000 Skips the Party

Number of stocks making new highs keeps climbing.

Anthera Pharmaceuticals Surpasses 50% Milestone For Screening Of Patients In RESULT Phase 3 Clinical Study Of Sollpura In Cystic Fibrosis

Anthera Pharmaceuticals Surpasses 50% Milestone For Screening Of Patients In RESULT Phase 3 Clinical Study Of Sollpura In Cystic Fibrosis

Anthera Pharmaceuticals To Present At Rodman & Renshaw's 18th Annual Global Investment Conference

Anthera Pharmaceuticals To Present At Rodman & Renshaw's 18th Annual Global Investment Conference

Anthera Pharmaceuticals To Participate In The Citi 12th Annual Biotech Conference

Anthera Pharmaceuticals To Participate In The Citi 12th Annual Biotech Conference

Anthera Announces Top Line Final Data From The Extension Period Of The Phase 2 BRIGHT-SC Study Of Blisibimod In Patients With IgA Nephropathy

Anthera Announces Top Line Final Data From The Extension Period Of The Phase 2 BRIGHT-SC Study Of Blisibimod In Patients With IgA Nephropathy

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study Of Sollpura Will Be Included In The European Cystic Fibrosis Clinical Trial Network

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study Of Sollpura Will Be Included In The European Cystic Fibrosis Clinical Trial Network

Anthera Announces FDA Orphan Drug Designation For Blisibimod For The Treatment Of IgA Nephropathy

Anthera Announces FDA Orphan Drug Designation For Blisibimod For The Treatment Of IgA Nephropathy

Anthera Pharmaceuticals Provides Business Update And Reports 2017 Second Quarter Financial Results

Anthera Pharmaceuticals Provides Business Update And Reports 2017 Second Quarter Financial Results

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study Of Sollpura Will Be Included In The Cystic Fibrosis Foundation Therapeutics Development Network

Anthera Pharmaceuticals Announces RESULT Phase 3 Clinical Study Of Sollpura Will Be Included In The Cystic Fibrosis Foundation Therapeutics Development Network

Anthera Announces Expansion Of Screening In European Sites In Phase 3 RESULT Clinical Study of Sollpura

Anthera Announces Expansion Of Screening In European Sites In Phase 3 RESULT Clinical Study of Sollpura

Load More

From Our Partners

Small med firms see increased buying
SeekingAlpha

Anthera Pharma to be delisted tomorrow; shares down 33.5%
SeekingAlpha

AzurRx hiring experienced CMO adds validation to MS1819, says H.C. Wainwright
The Fly

Achillion, Omeros, Ra Rx, Reata, ChemoCentryx, And Others In The IgA Nephropathy Space
SeekingAlpha

Anthera Fails Phase 3 Study, Time To Avoid
SeekingAlpha

U.S. Biotech/Pharma Sector Daily Observations Letter: March 13, 2018
SeekingAlpha

3 Things In Biotech, March 13, 2018: Uncertainty Abounds!
SeekingAlpha

Anthera Pharmaceuticals (ANTH) Reports Top Line Data From The RESULT Phase 3 Clinical Study Of Sollpura - Slideshow
SeekingAlpha

Your Daily Pharma Scoop: Coherus Biosciences Surges, Savara's Aironite Flops, Biogen's SPINRAZA
SeekingAlpha

Midday Gainers / Losers (3/12/2018)
SeekingAlpha

Healthcare - Top 5 Gainers / Losers as of 11:00 am (3/12/2018)
SeekingAlpha

Anthera downgraded to Underweight with 10c target at Piper Jaffray
The Fly

Anthera downgraded to Underweight from Overweight at Piper Jaffray
The Fly

Premarket Losers as of 9:05 am (3/12/2018)
SeekingAlpha

Anthera to terminate development of Sollpura after failed late-stage study
SeekingAlpha

Watchlist